☰

Patrick A. Mayes, Ph.D. - Publications

Affiliations: 
2008 University of Pennsylvania, Philadelphia, PA, United States 
Area:
Pharmacology, Oncology, Molecular Biology
Tree Info Similar researchers PubMed Report error

29 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Yadavilli S, Waight JD, Brett S, Bi M, Zhang T, Liu YB, Ellis C, Turner DC, Hahn A, Shi H, Seestaller-Wehr L, Jing J, Xie Q, Shaik JS, Ji X, ... ... Mayes PA, et al. Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade. Cancer Research Communications. 3: 1564-1579. PMID 37593752 DOI: 10.1158/2767-9764.CRC-22-0293  0.328
2021 Montes de Oca R, Alavi AS, Vitali N, Bhattacharya S, Blackwell C, Patel K, Seestaller-Wehr L, Kaczynski H, Shi H, Dobrzynski E, Obert L, Tsvetkov L, Cooper DC, Jackson H, Bojczuk P, ... ... Mayes P, et al. Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-Mediated Anti-Tumor Responses In Vivo. Molecular Cancer Therapeutics. PMID 34253590 DOI: 10.1158/1535-7163.MCT-21-0035  0.347
2015 Allen JE, Krigsfeld G, Patel L, Mayes PA, Dicker DT, Wu GS, El-Deiry WS. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Molecular Cancer. 14: 99. PMID 25927855 DOI: 10.1186/S12943-015-0346-9  0.612
2014 Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, Craigen J, Yates J, Gliddon L, Fieles W, Hoang B, Tunstead J, Christie AL, Kung AL, Richardson P, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 123: 3128-38. PMID 24569262 DOI: 10.1182/blood-2013-10-535088  0.346
2013 Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou JY, Wu GS, El-Deiry WS. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Science Translational Medicine. 5: 171ra17. PMID 23390247 DOI: 10.1126/Scitranslmed.3004828  0.662
2013 Mayes PA, Degenhardt YY, Wood A, Toporovskya Y, Diskin SJ, Haglund E, Moy C, Wooster R, Maris JM. Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition. International Journal of Cancer. Journal International Du Cancer. 132: E149-57. PMID 22948716 DOI: 10.1002/Ijc.27781  0.471
2013 Tai Y, Acharya C, Zhong MY, Cea M, Cagnetta A, Mayes PA, Craigen JL, Gliddon L, Smothers J, Christie AL, Kung AL, Richardson PG, Munshi NC, Anderson KC. Novel Fc-Engineered Anti-B Cell Maturation Antigen-Monomethyl Auristatin F Antibody-Drug Conjugate (GSK2857916) Induces Potent and Selective Anti-Multiple Myeloma Activity Via Enhanced Effector Function and Direct Tumor Cell Killing Blood. 122: 877-877. DOI: 10.1182/BLOOD.V122.21.877.877  0.357
2012 Qing G, Li B, Vu A, Skuli N, Walton ZE, Liu X, Mayes PA, Wise DR, Thompson CB, Maris JM, Hogarty MD, Simon MC. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell. 22: 631-44. PMID 23153536 DOI: 10.1016/J.Ccr.2012.09.021  0.529
2011 Dolloff NG, Mayes PA, Hart LS, Dicker DT, Humphreys R, El-Deiry WS. Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Science Translational Medicine. 3: 86ra50. PMID 21653830 DOI: 10.1126/Scitranslmed.3001384  0.61
2011 Mayes PA, Dolloff NG, Daniel CJ, Liu JJ, Hart LS, Kuribayashi K, Allen JE, Jee DI, Dorsey JF, Liu YY, Dicker DT, Brown JM, Furth EE, Klein PS, Sears RC, et al. Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1. Cancer Research. 71: 5265-75. PMID 21646472 DOI: 10.1158/0008-5472.Can-11-1383  0.688
2011 Katz SI, Zhou L, Ferrara TA, Wang W, Mayes PA, Smith CD, El-Deiry WS. FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy. International Journal of Oncology. 39: 91-100. PMID 21537838 DOI: 10.3892/Ijo.2011.1019  0.54
2011 Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, Diskin SJ, Attiyeh EF, Sennett R, Norris G, Laudenslager M, Wood AC, Mayes PA, Jagannathan J, Winter C, et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America. 108: 3336-41. PMID 21289283 DOI: 10.1073/Pnas.1012351108  0.458
2011 Wang K, Diskin SJ, Zhang H, Attiyeh EF, Winter C, Hou C, Schnepp RW, Diamond M, Bosse K, Mayes PA, Glessner J, Kim C, Frackelton E, Garris M, Wang Q, et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature. 469: 216-20. PMID 21124317 DOI: 10.1038/Nature09609  0.358
2011 Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Wu GS, El-Deiry WS. Abstract 4502: The small molecule TIC10 has potent anticancer efficacy mediated by induction of TRAIL production in normal and tumor cells Cancer Research. 71: 4502-4502. DOI: 10.1158/1538-7445.Am2011-4502  0.704
2011 Dolloff NG, Mayes P, Hart L, Dicker D, Humphreys R, El-Deiry W. Abstract 4101: Off-target lapatinib activity up-regulates TRAIL death receptors in colon cancer cells Cellular and Molecular Biology. 71: 4101-4101. DOI: 10.1158/1538-7445.Am2011-4101  0.571
2010 Qing G, Skuli N, Mayes PA, Pawel B, Martinez D, Maris JM, Simon MC. Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha. Cancer Research. 70: 10351-61. PMID 20961996 DOI: 10.1158/0008-5472.Can-10-0740  0.421
2010 Balamuth NJ, Wood A, Wang Q, Jagannathan J, Mayes P, Zhang Z, Chen Z, Rappaport E, Courtright J, Pawel B, Weber B, Wooster R, Sekyere EO, Marshall GM, Maris JM. Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target. Cancer Research. 70: 2749-58. PMID 20233875 DOI: 10.1158/0008-5472.Can-09-3844  0.462
2010 Dolloff NG, Hart LS, Mayes PA, Dicker DT, Humphreys RC, Gilmer TM, El-Deiry WS. Abstract 673: Novel anti-tumor activity of lapatinib derives from off-target up-regulation of TRAIL death receptors Cancer Research. 70: 673-673. DOI: 10.1158/1538-7445.Am10-673  0.638
2010 Allen JE, Patel L, Krigsfeld G, Mayes PA, Wu GS, El-Deiry WS. Abstract 5467: Breflate upregulates TRAIL gene transcription in Bax-null cells and induces TRAIL-mediated apoptosis independently of p53 in TRAIL-sensitive tumor lines Cancer Research. 70: 5467-5467. DOI: 10.1158/1538-7445.Am10-5467  0.682
2010 Cole KA, Huggins J, Laquaglia M, Diskin S, Attiyeh EF, Hulderman C, Han M, Bosse K, Jagannathan J, Mosse YP, Mayes P, Maris JM. Abstract 5263: An RNAi screen of the protein kinome identifiesCHEK1as a therapeutic target in neuroblastoma Cancer Research. 70: 5263-5263. DOI: 10.1158/1538-7445.Am10-5263  0.474
2010 Mayes PA, Diskin S, Attiyeh EF, Toporovskaya Y, Maris JM. Abstract 5256: The identification of fatty acid synthase (FASN) as a candidate oncogene and therapeutic target in neuroblastoma Cancer Research. 70: 5256-5256. DOI: 10.1158/1538-7445.Am10-5256  0.46
2010 Dolloff NG, Hart LS, Mayes PA, El-Deiry WS. Abstract 5044: Dual GSK-3β/CDK inhibitors induce multiple myeloma cell death and eliminate putative cancer stem cell populations Cancer Research. 70: 5044-5044. DOI: 10.1158/1538-7445.Am10-5044  0.568
2010 Diskin SJ, Bosse K, Mayes PA, LaQuaglia M, Attiyeh EF, Laudenslager M, Mosse YP, Diamond M, Belcastro L, Toporovskaya Y, Norris G, Hou C, Wang K, Zhang H, Kim C, et al. Abstract 3866: Identification ofNME7as a predisposition locus and candidate oncogene in neuroblastoma Cancer Research. 70: 3866-3866. DOI: 10.1158/1538-7445.Am10-3866  0.479
2009 Qing G, Mayes P, Pawel B, Martinez D, Maris JM, Simon MC. Abstract C15: Combinatorial regulation of neuroblastoma tumor progression by HIF1α and N‐myc transcriptional factors Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-C15  0.507
2008 Kuribayashi K, Krigsfeld G, Wang W, Xu J, Mayes PA, Dicker DT, Wu GS, El-Deiry WS. TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biology & Therapy. 7: 2034-8. PMID 19106633 DOI: 10.4161/Cbt.7.12.7460  0.602
2008 Mayes PA, Dicker DT, Liu YY, El-Deiry WS. Noninvasive vascular imaging in fluorescent tumors using multispectral unmixing Biotechniques. 45: 459-464. PMID 18855773 DOI: 10.2144/000112946  0.455
2006 Mayes PA, El-Deiry WS. The complementary roles of the extrinsic and intrinsic apoptotic pathways in promoting the death of cancer cells. Cancer Journal (Sudbury, Mass.). 12: 247-9. PMID 16925967 DOI: 10.1097/00130404-200607000-00001  0.577
2006 Kuribayashi K, Mayes PA, El-Deiry WS. What are caspases 3 and 7 doing upstream of the mitochondria? Cancer Biology & Therapy. 5: 763-5. PMID 16921264 DOI: 10.4161/Cbt.5.7.3228  0.518
2005 Mayes PA, Campbell L, Ricci MS, Plastaras JP, Dicker DT, El-Deiry WS. Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment. Cancer Biology & Therapy. 4: 1068-74. PMID 16294025 DOI: 10.4161/Cbt.4.10.2255  0.588
Show low-probability matches.